Previous studies indicate that epigenetic silencing of tumor suppressors (e.g., via PTEN promoter hypermethylation) is a central driver of aberrant PI3K/AKT activation (Kang, Lee & Kim, 2002). The gene discussed is PTEN; the disease is neoplasm.